pitalized patients yearly in the United States [4] [5] . Clinical manifestations range from asymptomatic colonization to severe diarrhea, pseudomembranous colitis, toxic megacolon, and death [6] .
To our knowledge, the only previous comprehensive report that described the incidence of CDI in Canada was conducted in 1997 by the Canadian Nosocomial Infection Surveillance Program (CNISP). The CNISP examined the incidence of health care-associated CDI (HA CDI) within 19 hospitals in 8 Canadian provinces over a six-week surveillance period and found that HA CDI was most frequent in older patients and those hospitalized 12 weeks in medical or surgical wards [7] . The incidence of HA CDI cases was 66 infections per 100,000 patient-days (95% CI, 3.75-95.1) and 5.9 infections per 1000 patient hospital admissions (95% CI, 3.4-8.4). A subsection of the initial study reported that of the 41 patients (15.2%) who died during the 30 days after onset of disease, 4 (1.5%) of these deaths were attributable to HA CDI [8] . These reports were pivotal in providing baseline rates with which other Canadian hospitals could compare, and they are currently the only available description of the burden of HA CDI in Canadian hospitals. More-recent reports have suggested an increase in incidence, severity, and/or risk of relapse of CDI in Canada [9] . Since the last half of 2002, several hospitals in Quebec, Canada (located mostly in Montreal and Sherbrooke), have experienced a dramatic increase in the incidence, severity, and number of relapses associated with HA CDI [9, [10] [11] [12] [13] , with mean rates of 25 cases per 1000 hospital admissions [14] .
Similar reports have been published in other industrialized countries [15, 16] . One of the earliest North American reports of highly lethal CDI was from Pittsburgh, Pennsylvania, in 2000 [17] . An analysis of US hospital discharge data revealed that CDI rates increased abruptly beginning in 2001, with a doubling of national rates between 2000 and 2003 [18] . This increase was most prominent for patients у65 years of age. Reports also suggested that the attributable mortality rate (or fatality rate) had increased as well. On the basis of the data from Quebec, the attributable mortality rate for CDI was estimated to be 6.9% [11] .
The CNISP elected to re-examine the incidence of HA CDI in Canada, with an emphasis on patient outcomes. The objectives of the surveillance were to determine the incidence and burden of illness associated with HA CDI in CNISP hospitals and to determine whether there was an increase in severe outcomes (mortality and morbidity associated with CDI) in 2005, compared with 1997. The present report describes the epidemiology of HA CDI involving adults aged у18 years who were hospitalized in Canadian acute care facilities that participate in CNISP.
METHODS
The CNISP is a collaborative effort of the Canadian Hospital Epidemiology Committee, a subcommittee of the Association of Medical Microbiology and Infectious Disease Canada, the National Microbiology Laboratory, and the Centre for Communicable Diseases and Infection Control of the Public Health Agency of Canada (PHAC). Twenty-nine hospitals in 9 Canadian provinces participated in a prospective surveillance for HA CDI from 1 November 2004 through 30 April 2005. All hospitalized patients aged у18 years were eligible for enrollment.
The case definition for CDI was (1) documented diarrhea (6 watery stools during the previous 36 h, 3 unformed stools in a 24-h period over 2 days, or 8 unformed stools during a 48-h period), (2) fever, abdominal pain, and/or ileus plus laboratory confirmation of a stool sample positive for C. difficile toxin A or B or a positive tissue culture assay, (3) diagnosis of pseudomembranous colitis on colonoscopy, or (4) histological or pathological diagnosis of CDI. The infection was considered to be health care associated if the patient's symptoms occurred at least 72 h after hospital admission or if symptoms resulted in readmission of a patient who had been hospitalized within the 2 months before the symptom onset date and who was not a resident in a long-term care facility or nursing home.
Eligible patients were identified by daily review of results of toxin assay of C. difficile in stool samples tested in the clinical microbiology laboratory or a review of relevant pathology reports or operating room records. The charts of patients with stool samples positive for C. difficile toxin were examined by experienced and trained infection-control professionals or trained research personnel associated with each hospital. Basic demographic data were collected on all patients, as well as the date of onset of diarrhea, initial treatment of CDI, and medical and treatment inventions.
Data regarding adverse events were collected 30 days after the date of diarrhea onset and included information about death, intensive care unit admission, surgery, bowel perforation, gastrointestinal bleeding, toxic megacolon, dehydration, hypokalemia, and relapse. All deaths were assessed by the hospital epidemiologist or a designated physician to determine whether the death was attributable to CDI-either CDI that was directly related to the death or CDI that indirectly contributed to the patient's death but was not the primary cause. Severe outcome was defined as an admission to the intensive care unit for complications of CDI, colectomy due to CDI, and/or death attributable to CDI.
Data were collected and entered manually onto patient dataextraction forms and were forwarded to PHAC for data entry and analysis. A unique identifier linked to the patient name was used only to identify patients at the participating hospital and was not transmitted to PHAC. Because this surveillance project was observational and did not involve any alteration in patient care, Review Ethics Board approval was not required by PHAC. However, individual institutional Review Ethics Board approval was obtained at some of the participating hospitals.
Statistical analysis. The CNISP hospitals were grouped by Canadian province or region, and rates of HA CDI were calculated using both the number of patient admissions and the number of patient-days for denominators. Crude mortality and attributable mortality rates were determined using the criteria described above. Descriptive and univariate analyses were performed. To assess differences between patient populations, continuous variables were expressed by means and were compared using Student's t test. Categorical variables were expressed as proportions and were compared using the x 2 test and Fisher's exact test when necessary. All tests were 2 tailed, and a P value !.05 was considered to be statistically significant. Relative risks with corresponding 95% CIs were calculated according to standard methods. A multivariate logistic regression model was used to assess patient factors associated with a severe outcome. Variables were selected for entry into the regression model if у10 of the patients had the characteristic and the variables were significantly associated with a severe outcome ( ) P р .25 in the univariate analysis. The goodness of fit of the final model was tested using the deviance test. Statistical analysis was conducted using SAS, version 9.1 (SAS Institute).
RESULTS
A total of 1430 adults with HA CDI were identified during the 6-month surveillance period. There were 13 hospitals in Ontario; 4 in Alberta; 2 each in British Columbia, Saskatchewan, Manitoba, Quebec, and Newfoundland; and 1 each in New Brunswick and Nova Scotia. The overall rate of HA CDI for adult patients admitted to these hospitals for this 6-month period was 4.6 cases per 1000 patient admissions and 65 cases per 100,000 patient-days (table 1). The rate was higher in the hospitals in Quebec than it was in hospitals in the rest of Canada (12.8 vs. 4.0 cases per 1000 admissions and 130 vs. 58 cases per 100,000 patient-days;
). At 30 days after onset of P ! .001 HA CDI, 233 patients had died from all causes, for a mortality rate of 16.3 deaths per 100 cases. Of these, 31 deaths (2.2% of all patients) were a direct result of CDI, and 51 deaths (3.6% of all patients) were indirectly related to CDI, for a total attributable mortality of 5.7% ( Oncology/hematology unit 53 (4) 31 (7) 22 (2) !.001
Combined medicine/surgical 45 (3) 16 (4) 29 (3) NS BMT/transplant unit 22 (2) 18 (4) were prescribed metronidazole, 230 (16%) received vancomycin, and 51 (4%) also received probiotics. A total of 168 patients (12%) were receiving both metronidazole and vancomycin. Probiotics were given in addition to either metronidazole or vancomycin. Patients у65 years of age were 1.5 times more likely to receive vancomycin than were patients aged 18-64 years (18% vs. 12%, ). Patients with CDI P p .005 in the province of Quebec were 9 times more likely to receive vancomycin than were patients in the rest of Canada (56% vs. 6%, ) (table 4). P ! .001 A total of 319 adult patients with HA CDI (22%) developed complications during the first 30 days after onset of CDI; 104 patients (7.3%) had a severe outcome (table 5). Relapse was the most common complication, which involved 125 patients (9%). Dehydration was more likely to be seen in the patients у65 years of age (7% vs. 3%;
), whereas gastrointes-P p .005 tinal bleeding that required blood transfusions was more likely to be seen in adults aged 18-64 years (2% vs. 0.7%; P p ). .029
The attributable mortality was 3.5 times higher in patients aged 165 years, compared with the patients aged 18-64 years (7.3% vs. 2.2%;
). The attributable mortality was high-P ! .001 est in patients aged 190 years: 14.7%. For patients aged 81-90 years, the attributable mortality was 10.4%; at 71-80 years of age, the attributable mortality was 5.9%; at 61-70 years of age, the attributable mortality was 5.4%; at 51-60 years of age, the attributable mortality was 2.8%; and at age of !50, the attributable mortality was 3.0%. For univariate analysis, the factors that were associated with a severe outcome are presented in table 6. In the multivariate logistic regression model for severe outcome, the following characteristics were all independently associated: advanced age, hospital admission from another hospital or a long-term care facility, liver disease, receipt of vancomycin as initial treatment, and having a change in the initial treatment for HA CDI (table  7) . Location of the patient in the hospital at infection onset was not independently associated with severe outcome.
DISCUSSION
The results from this surveillance project represent the most comprehensive surveillance of HA CDI in adults hospitalized in Canada that have been reported to date. The rates are remarkably similar to those found in our previous study [7] ; however, we found wide variations in HA CDI among the participating hospitals (range, 20-167 cases per 100,000 patients-days). The underlying reasons for this variation remain unclear. There may be a surveillance artifact: in different hospitals, the threshold for testing stool samples for C. difficile toxin may vary (especially in Quebec, where heightened public attention may have led to increased testing). Variation in toxin testing methods may also contribute, because these tests are not uniformly sensitive [19] Although it has been suggested that these discrepant findings may be the result of differing methodologies [20] , this is not the case for our surveillance. Our study was conducted using a previously piloted methodology with a standardized case definition and patient questionnaire. However, previous studies have suggested that antibiotic usage; the physical layout of the institution, including the presence or absence of sinks for hand washing; and both the infection-prevention and infection-control practices and isolation practices, particularly in adherence to and agents used for hand hygiene, have played a role in the overall incidence of HA CDI [3, 21, 22] .
Wide variations are also seen among provinces and regions in Canada. The rate of HA CDI in CNISP hospitals in central Canada (e.g., Ontario and Quebec) was more than twice the incidence of HA CDI in other areas of the country (7.0 vs. 2.8 cases per 1000 hospital admissions and 91 vs. 41 per 100,000 patient-days;
). Although there is notable stability in P ! .001 the rate of HA CDI in Canada since 1997 (65 vs. 66 cases per 100,000 patient-days in 1997); our surveillance found a significant increase in the number of deaths attributable to HA CDI. Compared with the CNISP surveillance conducted in 1997, the percentage of deaths directly or indirectly related to HA CDI has increased almost 4-fold (from 1.5% to 5.7%;
) [8] . These results are comparable, because we used P ! .001 the same methodology with the current surveillance that was used in 1997, and this would indicate that HA CDI is an emerg- (8) 198 (20) !.001
Related to CDI 82 (6) 9 (2) 73 (7) !.001
Directly related 31 1 30
Indirectly related 51 8 43
Severe outcome b 104 (7) 17 (4) 87 (9) .001 ing cause of mortality among hospitalized patients in Canada, especially among older patients. Our results are similar to those of other recent studies, which demonstrated that age-specific attributable mortality increased sharply after age 60 years [23] . This may explain, in part, why we found a similar rate of HA CDI during 2004-2005, compared to 1997, whereas the attributable mortality increased sharply-by 400%. In the present study, 50% of the patients were у73 years of age; in 1997, the patients were somewhat younger, with 50% of patients у68 years of age. The increase in the attributable mortality between 1997 and the current study may also be related to the heightened awareness of the severe outcomes associated with CDI, especially in the provinces that have experienced numerous outbreaks in recent years. Although the hospital epidemiologist or another qualified physician determined the cause of death in patients with HA CDI, attribution of mortality is always subjective and can be interpreted differently by different clinicians. In Quebec, all death rates are reviewed by 2 physicians before a consensus is reached. In the participating hospitals from other provinces, only 1 assessment was performed. We found that the attributable mortality from HA CDI was much higher in the CNISP hospitals in Quebec, followed by British Columbia and Ontario. However, although only 2 hospitals in Quebec participated in the surveillance project, our findings support previously published reports describing increased fatality in Quebec [9] [10] [11] [12] [13] [14] 23] .
Although the analysis of the C. difficile strain characterization was not the object of this study, subsequent examination of the strains on a subset of the CNISP surveillance revealed that the NAP1/027 "hypervirulent" strain of C. difficile, first described in Quebec before the 2004-2005 surveillance period, was now isolated in 6 more Canadian provinces, but mostly in Quebec, British Columbia, and Ontario [24] . Previous studies have found a definite association between NAP1/027 and moresevere disease, especially in older patients with CDI [23] [24] [25] [26] .
The association between vancomycin use as therapy for HA CDI and a worse outcome is contradictory to recent data that suggest that it is superior to metronidazole [27, 28] . We believe that this association is attributable to 2 factors. First, more vancomycin was used in Quebec, where more severe CDI outcomes were observed. Second, we believe that vancomycin was used preferentially for patients with more severe disease at the time of CDI diagnosis, a practice ensuing from the influence of Montreal hospitals, which used vancomycin this way since the outbreaks in 2002 (M. Miller, personal communication) . Therefore, the association between vancomycin use as CDI therapy and severe outcome should be viewed with caution. Approximately 70% of all vancomycin use was in Quebec, where the majority of infecting isolates are of the NAP1/027 type and where severe CDI is more common than it is in other provinces. In Quebec, vancomycin has been officially recommended as first-line therapy for severe CDI since 2004. Thus, the association of vancomycin and severe disease is most likely a correlation that is attributable to the provincial recommendations for treatment of this disease. Analysis of outcome and vancomycin use in patients outside Quebec failed to show a correlation, as expected.
There are limitations to our study, primarily inherent to large multicenter surveillance activities. First, although data collection was conducted by experienced and trained infection-control professionals using standardized definitions, the data collection remained unmonitored, and there may be inconsistencies between hospitals in identifying a case of HA CDI. Because the diagnosis of HA CDI is frequently based on laboratory findings, there may be some variability in the microbiological laboratory testing and identification of C. difficile at the different hospitals. Finally, the populations examined in this survey were in major teaching hospitals and so are likely not entirely representative of all hospitalized adult patients in Canada.
Despite these limitations, the data presented in this study are an important contribution to understanding the impact of HA CDI in adults admitted to Canadian hospitals participating in CNISP. The results are sufficiently robust to be used as baseline indicators for future comparisons within similar large teaching hospitals. Follow-up surveillance in the same hospitals will allow us to monitor the incidence of HA CDI, to follow the spread of C. difficile strains-more specifically, the spread of NAP1/027-in Canada, and to assess the impact on the morbidity and mortality associated with HA CDI. In addition, follow-up surveillance will allow for the assessment of seasonal variations in HA CDI. CDI is known to be more common in hospitalized patients during winter months-a factor in our decision to perform a survey during November-April [29] . Although our hospitals have reported similar rates throughout the year, year-round surveillance may show a lower national rate of HA CDI. National surveillance also provide opportunities for interhospital collaboration that may lead to more standardized use of surveillance methodology, including application of definitions and case finding methods, and effective infection-prevention and infection-control measures.
